Prof. Jianhua Zheng is a distinguished researcher at the Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, recognized for his impactful contributions to infectious disease research and translational immunology. With 25 peer-reviewed publications and over 322 citations across 290 citing documents, his work reflects consistent scholarly influence in pathogen biology, immune mechanisms, and diagnostic innovation. Prof. Zheng’s research portfolio spans high-priority global health challenges, including SARS-CoV-2 variant immunology and tuberculosis biomarker discovery. His recent open-access publications—such as the development of a broadly neutralizing antibody effective against multiple SARS-CoV-2 Omicron sub-variants and integrated neutrophil proteomic–transcriptomic profiling for TB diagnosis—demonstrate his commitment to advancing precision medicine and public health solutions. He frequently collaborates with multidisciplinary teams, reflected in more than 100 co-authors, indicating a strong network across molecular biology, clinical research, and computational sciences. Prof. Zheng’s work bridges basic science with clinical application, generating insights that support vaccine development, therapeutic antibody engineering, and early diagnostic strategy design. Through rigorous methodology, open-access dissemination, and global collaborations, his research contributes meaningfully to strengthening infectious disease surveillance, improving patient outcomes, and enhancing preparedness for emerging pathogens. His sustained scholarly productivity and growing citation impact underscore his role as a leading scientist shaping contemporary biomedical research and contributing to international efforts in disease control and health security.
Profiles: Scopus
Featured Publications
1. Chen, Z., Feng, L., Wang, L., Zhang, L., Zheng, B., Fu, H., Li, F., Liu, L., Lv, Q., Deng, R., Xu, Y., Hu, Y., Zheng, J., Qin, C., Bao, L., Wang, X., & Jin, Q. (2025). A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Signal Transduction and Targeted Therapy, 10, 14.
2. Yang, J., Lv, Z., Liu, L., Zhang, H., Hu, J., Geng, X., Xin, H., Liu, Z., Gao, L., Zhang, X., Xu, Y., Liu, R., Jin, Q., & Zheng, J. (2025). Peripheral blood neutrophil proteomic profiling with transcriptomic data integration reveals biomarkers for tuberculosis infection diagnosis. EBioMedicine, 120, 105945. https://doi.org/10.1016/j.ebiom.2025.105945 Cited by: [not yet available / very recent
3. Liu, L., Xu, D., Chen, F., Cai, S., Wei, J., Deng, J., Zheng, J., Jin, Q., & Lun, W. (2023). Identification of potential biomarkers for diagnosis of syphilis from the cerebrospinal fluid based on untargeted metabolomic analysis. Molecular Omics, 19(6), 484–491.
4. Zheng, J., Liu, L., Wei, C., Liu, B., & Jin, Q. (2022). Characterization of O-mannosylated proteins profiling in Bacillus Calmette-Guérin via gel-based and gel-free approaches. IUBMB Life, 74(3), 221–234.
5. Deng, J., Liu, L., Yang, Q., Wei, C., Zhang, H., Xin, H., Pan, S., Liu, Z., Wang, D., Liu, B., Gao, L., Liu, R., Pang, Y., Chen, X., Zheng, J., & Jin, Q. (2021). Urinary metabolomic analysis to identify potential markers for the diagnosis of tuberculosis and latent tuberculosis. Archives of Biochemistry and Biophysics, 704, 108876.
Dr. Jianhua Zheng advances global infectious disease science through high-impact research on SARS-CoV-2 neutralizing antibodies and tuberculosis biomarkers. His work accelerates diagnostic precision and therapeutic innovation, strengthening global preparedness for emerging pathogens.